No. 4: CAR - T takes a backseat Research into chimeric antigen receptor T - cell (CAR - T) therapy has captured the attention of investors over the past two years, but safety risks could emerge as trial sizes increase, and that could help shift attention to other promising anti-cancer approaches, including NantKwest's (NASDAQ: NK) natural
killer cell approach and soon - to - IPO Editas» CRISPR / Cas approach.
Not exact matches
It's the second approval for this pioneering
approach to cancer treatment, which involves re-engineering patients» own immune
cells to become cancer
killers, after the FDA's approval of Novartis» Kymriah in August.
Similar
approaches using
killer T
cells are already being investigated as a cancer treatment, with some promising results.
Natural
killer cells serve important roles in clearing non-type 2 inflammatory
cells, so identification of a defect in NK
cell function in severe asthma provides a window for the development of new therapeutic
approaches.
The Dotiwala laboratory uses cellular, molecular, biochemical and omics
approaches, as well as sophisticated in vivo imaging, to dissect the mechanism by which
cell - based immunity (neutrophils, macrophages and
killer lymphocytes) is activated in the presence of different pathogenic bacteria, such as intra - and extracellular bacteria, fungi and protozoa.
Using a combination of biochemical and genetic
approaches, Darnell's lab discovered that the immune systems of PND patients thwart tumors with what is essentially an antiviral response: The patients» T
cells produce CD8 +
killer T
cells that recognize the neuronal antigens present within their tumors.